Acrivon Q1 net loss $12.8M vs $7.2M YoY; cash $159.5M; FDA Fast Track for ACR-368

Acrivon Therapeutics, Inc.

2023-Q1 EPS reported -$0.58

Net loss $12.8M for Q1 2023, widened from $7.2M in Q1 2022; R&D expense $9.8M (up from $6.1M).
Cash, equivalents and marketable securities $159.5M as of March 31, 2023; runway into Q4 2024.
FDA granted Fast Track designation for ACR-368 monotherapy in OncoSignature-positive platinum-resistant ovarian and endometrial cancer.
Phase 2 registrational trial of ACR-368 continues enrolling; initial clinical readouts expected H2 2023.
Advancing WEE1 and PKMYT1 inhibitor programs toward IND-enabling studies in 2023.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Acrivon Therapeutics, Inc. reported the quarter ended March 31, 2023 results: net income $12.8 million.

Period: the quarter ended March 31, 2023
Net income: $12.8 million
Result: reported results

Exact text from the filing

Net loss for the quarter ended March 31, 2023 was $12.8 million

View on SEC.gov

Browse all earnings releases →

Acrivon Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-23-138948

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.